Inhalants: The Substance Class Nobody Talks About
Legal, cheap, and lethal on the first use. Underappreciated in addiction education — especially for kids.
Body — 8 lenses: [Science: solvents act as NMDA antagonists + GABA modulators; nitrites as smooth-muscle relaxants via NO; aerosols variable. Biology: sudden sniffing death syndrome (cardiac sensitization to catecholamines), hypoxia, leukoencephalopathy (toluene), hepatorenal toxicity. Psychology: typically first-used age 9–13, often precedes other substance use; associated with ACEs. Policy: mostly not controlled (volatile solvents legal); age-of-sale laws for specific products; poppers under ambiguous FDA status. Trends: SAMHSA NSDUH tracks; resurgence concerns in some regions. Social: historically framed as “kid’s drug”; underrepresented in most SUD curricula. Treatment: abstinence-based (no meds); family therapy; CRAFT. Harm reduction: never use alone, ventilation, don’t use with CNS depressants, education for parents and schools.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionYouth & Young AdultsFamilies & CaregiversPeer-Reviewed Research
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.